Orthocell Market Cap per Employee

What does Orthocell do? Orthocell Ltd develops and commercializes cell therapies and related technologies focused on regenerating mobility for patients with bone and soft tissue injuries. The company's products include CelGro, a collagen medical device using SMRT manufacturing for tissue reconstruction in dental and orthopedic applications, Striate+ for dental GBR, Remplir for peripheral nerve reconstruction, and SmrtGraft for tendon repair. Autologous cell therapy, particularly its tendon cell therapy in development in the United States, targets chronic tendon injuries through advanced injectable cellular therapy for cartilage and tendon regeneration. Orthocell's primary customers are healthcare providers and medical institutions requiring advanced tissue repair solutions. The company generates revenue through the sale of its medical devices and cell therapy products, with CelGro and related SMRT manufacturing processes forming a core part of its commercial portfolio. Its autologous tendon therapy development in the U.S. represents a key growth segment targeting chronic tendon injury treatments. The company's product portfolio is structured around regenerative medicine applications, with CelGro serving dental and orthopedic markets, Striate+ specifically for dental GBR, Remplir addressing nerve reconstruction needs, and SmrtGraft focused on tendon repair. Orthocell's commercial strategy emphasizes direct sales of these products to healthcare professionals and institutions seeking innovative solutions for tissue repair and regeneration. Orthocell is one of the most popular companies on Eulerpool.